

Human LRG1 ELISA Kit

Vertrieb:

L O X O GmbH Immunbiologie Biochemie, Produkte und Systeme Postfach 11 30 69215 Dossenheim Telefon +49 (0) 62 21 - 86 80 23 FAX +49 (0) 62 21 - 86 80 255

Assaypro LLC 3400 Harry S Truman Blvd St. Charles, MO 63301 T (636) 447-9175 F (636) 395-7419

www.assaypro.com

Hinweis/Note:

Der Packungsbeileger dient nur als erste Information. Der relevante Packungsbeileger liegt der Ware bei.

The datasheet is only a first information. The relevant datasheet is included with the product.

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.

Thank you for choosing Assaypro.

Assay Summary

Step 1. Add 50 μ l of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μ l of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μ l of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μ l of Chromogen Substrate per well. Incubate 25 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key



Consult instructions for use.

Assay Template

12								
11								
10								
o								
00								
7								
9								
ī.								
4								
m								
2								
н								
	А	В	O	Q	ш	т	9	Ξ

AssayMax Human Leucine-rich alpha-2-Glycoprotein 1 (LRG1) ELISA Kit

Catalog No. EL2301-1 Lot No. 032271513

Introduction

Leucine-rich alpha-2-glycoprotein 1, in humans, is a protein that is encoded by the *LRG1* gene. LRG1 belongs to the leucine-rich repeat (LRR) family of proteins, which has been shown to be involved in cell adhesion and development, protein-protein interaction, and signal transduction.

Additionally, LRG1 has been shown to be involved in the promotion of neovascularization, causing a switch in transforming growth factor beta (TGF-beta) signaling in endothelial cells. LRG1 binds to the accessory receptor endoglin and promotes signaling via the ALK1-Smad1/5/8 pathway. LRG1 is expressed during granulocyte differentiation (1, 2). LRG1 protein levels show significant elevation in acute appendicitis (3). Serum LRG1 has been shown to be significantly elevated in women with ovarian cancer when compared to healthy women and women with benign gynecological disease (4). LRG1 may be a possible therapeutic target for the treatment of diseases with aberrant neovascularization (2).

Principle of the Assay

The AssayMax Human LRG1 ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for detection of human LRG1 in plasma, serum, urine, saliva, milk, CSF, and cell culture samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures human LRG1 in less than 4 hours. A polyclonal antibody specific for human LRG1 has been pre-coated onto a 96-well microplate with removable strips. LRG1 in standards and samples is sandwiched by the immobilized polyclonal antibody and biotinylated polyclonal antibody specific for human LRG1, which is recognized by a streptavidin-peroxidase conjugate. All unbound material is then washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

 Prepare all reagents (working diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate) as instructed, prior to running the assay.

- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this protocol. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- This kit is for research use only.
- The kit should not be used beyond the expiration date.

Reagents

- **Human LRG1 Microplate:** A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human LRG1.
- **Sealing Tapes:** Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human LRG1 Standard: Human LRG1 in a buffered protein base (40 ng, lyophilized).
- **Biotinylated Human LRG1 Antibody (50x):** A 50-fold concentrated biotinylated polyclonal antibody against human LRG1 (140 µl).
- MIX Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- Streptavidin-Peroxidase Conjugate (SP Conjugate): A 100-fold concentrate (80 μl).
- **Chromogen Substrate**: A ready-to-use stabilized peroxidase chromogen substrate tetramethylbenzidine (8 ml).
- **Stop Solution**: A 0.5 N hydrochloric acid to stop the chromogen substrate reaction (12 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Diluent (1x) may be stored for up to 30 days at 2-8°C.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm.
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel).
- Deionized or distilled reagent grade water.

Sample Collection, Preparation, and Storage

- Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes. Dilute samples 1:10000 into MIX Diluent and assay. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x g for 10 minutes, and remove serum. Dilute samples 1:10000 into MIX Diluent and assay. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **Urine:** Collect urine using sample pot. Centrifuge samples at $800 \times g$ for 10 minutes and assay. The undiluted samples can be stored at -20° C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Saliva: Collect saliva using sample tube. Centrifuge samples at 800 x g for 10 minutes. Dilute saliva samples 1:50 into MIX Diluent and assay. The undiluted samples can be stored at -20 °C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Milk: Collect milk using sample tube. Centrifuge samples at 800 x g for 10 minutes. Dilute milk samples 1:500 into MIX Diluent and assay. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **Cell Culture Supernatants:** Centrifuge cell culture media at 3000 x g for 10 minutes to remove debris. Collect supernatants and assay. The samples can be stored at -20 °C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **CSF:** Collect cerebrospinal fluid (CSF) using sample pot. Centrifuge samples at 3000 x g for 10 minutes. Dilute samples 1:50 into MIX Diluent and assay. The undiluted samples can be stored at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.

Refer to Sample Dilution Guidelines below for further instruction.

	Guidelines for Dilutions of 1:100 or Greater (for reference only; please follow the protocol for specific dilution suggested)			
	1:100	10100	1:10000	
۸)	4 ul cample, 206 ul huffer/100v)	۸۱	Aul cample (206 ul huffer (100v)	
(A)	4 ul sample: 396 μl buffer(100x) = 100 fold dilution	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000 fold dilution	
	Assuming the needed volume is less than or equal to 400 μ l.		Assuming the needed volume is less than or equal to 400 μ l.	
	1:1000		1:100000	
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x)	A) B)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x)	
	= 1000 fold dilution Assuming the needed volume is less than	C)	24 μl of B : 216 μl buffer (10x) = 100000 fold dilution Assuming the needed volume is less than	
	or equal to 240 μl.		or equal to 240 μl.	

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- MIX Diluent Concentrate (10x): If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. Dilute the MIX Diluent Concentrate 1:10 with reagent grade water. Store for up to 30 days at 2-8°C.
- Standard Curve: Reconstitute the 40 ng of Human LRG1 Standard with 2 ml of MIX Diluent to generate a 20 ng/ml standard stock solution. Allow the standard to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting the standard stock solution (20 ng/ml) 1:2 with MIX Diluent to produce 10, 5, 2.5, 1.25, 0.625, and 0.313 ng/ml solutions. MIX Diluent serves as the zero standard (0 ng/ml). Any remaining solution should be frozen at -20°C and used within 30 days.

Standard Point	Dilution	[Human LRG1] (ng/ml)
P1	1 part Standard (20 ng/ml)	20.00
P2	1 part P1 + 1 part MIX Diluent	10.00
P3	1 part P2 + 1 part MIX Diluent	5.000
P4	1 part P3 + 1 part MIX Diluent	2.500
P5	1 part P4 + 1 part MIX Diluent	1.250
P6	1 part P5 + 1 part MIX Diluent	0.625
P7	1 part P6 + 1 part MIX Diluent	0.313
P8	MIX Diluent	0.000

- Biotinylated Human LRG1 Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 1:50 with MIX Diluent. Any remaining solution should be frozen at -20°C.
- Wash Buffer Concentrate (20x): If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. Dilute the Wash Buffer Concentrate 1:20 with reagent grade water.
- **SP Conjugate (100x):** Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 1:100 with MIX Diluent. Any remaining solution should be frozen at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 μ l of Human LRG1 Standard or sample per well. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash five times with 200 µl of Wash Buffer manually. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a machine, wash six times with 300 µl of Wash Buffer and then invert the plate, decanting the contents; hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 μ l of Biotinylated Human LRG1 Antibody to each well and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 μ l of Streptavidin-Peroxidase Conjugate to each well and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 μl of Chromogen Substrate per well and incubate for 25 minutes or till the optimal blue color density develops. Gently tap plate to ensure thorough mixing and break the bubbles in the well with pipette tip.
- Add 50 μ l of Stop Solution to each well. The color will change from blue to yellow.
- Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections.
 Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points

after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance on the y-axis. The best-fit line can be determined by regression analysis using log-log or four-parameter logistic curve-fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Typical Data


• The typical data is provided for reference only. Individual laboratory means may vary from the values listed. Variations between laboratories may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
P1	20.00	2.512	2.495
PI	20.00	2.477	2.495
P2	10.00	1.762	1.733
FZ	10.00	1.704	1.733
P3	5.000	1.003	1.012
r5	3.000	1.022	1.012
P4	2.500	0.454	0.459
F4	2.500	0.465	0.433
P5	1.250	0.281	0.272
r J		0.264	0.272
P6	0.625	0.173	0.171
F U	0.025	0.169	0.171
P7	0.313	0.141	0.140
Γ/	0.313	0.139	0.140
P8	0.000	0.101	0.101
го	0.000	0.101	0.101
Sample: Po	ol Normal,	0.725	0.720
Sodium Citrate I	Plasma (10000x)	0.715	0.720

Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.

Human LRG1 Standard Curve



Performance Characteristics

- The minimum detectable dose of LRG1 as calculated by 2SD from the mean of a zero standard was established to be 0.17 ng/ml.
- Intra-assay precision was determined by testing replicates of three milk samples in one assay.
- Inter-assay precision was determined by testing three milk samples in twenty assays.

	Intra-Assay Precision			Inter	-Assay Prec	ision
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	3.8%	3.9%	3.6%	7.8%	7.7%	7.6%
Average CV (%)	3.8%				7.7%	

Recovery

Standard Added Value	1 – 10 ng/ml
Recovery %	91 – 110%
Average Recovery %	95%

Linearity

Plasma and serum samples were serially-diluted to test for linearity.

Average Percentage of Expected Value (%)			
Sample Dilution	Plasma	Serum	
1:5000	101%	105%	
1:10000	100%	97%	
1:20000	96%	102%	

Cross-Reactivity

Species	Cross Reactivity (%)
Beagle	None
Bovine	None
Monkey	15%
Mouse	None
Rat	None
Swine	None
Rabbit	None
Human	100%

• No significant cross-reactivity found with alpha-2-HS-Glycoprotein and alpha-1-Acid Glycoprotein at 1 ug/ml.

Troubleshooting

Issue	Causes	Course of Action
	Use of expired components	 Check the expiration date listed before use. Do not interchange components from different lots.
Precision	Improper wash step	 Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique.
Low	Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
	Inconsistent volumes loaded into wells	 Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.

	Insufficient mixing of reagent dilutions Improperly sealed microplate	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions. Check the microplate pouch for proper sealing. Check that the microplate pouch has no punctures. Check that three desiccants are inside the microplate pouch prior to sealing.
Signal	Microplate was left unattended between steps	Each step of the procedure should be performed uninterrupted.
r High	Omission of step Steps performed in incorrect order	 Consult the provided procedure for complete list of steps. Consult the provided procedure for the correct order.
Unexpectedly Low or High Signal Intensity	Insufficient amount of reagents added to wells	Check pipette calibration.Check pipette for proper performance.
[]	Wash step was skipped	 Consult the provided procedure for all wash steps.
cte	Improper wash buffer	Check that the correct wash buffer is being used.
edxe	Improper reagent preparation	 Consult reagent preparation section for the correct dilutions of all reagents.
n	Insufficient or prolonged incubation periods	Consult the provided procedure for correct incubation time.
Deficient Standard Curve Fit	Non-optimal sample dilution	 Sandwich ELISA: If samples generate OD values higher than the highest standard point (P1), dilute samples further and repeat the assay. Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples further and repeat the assay. User should determine the optimal dilution factor for samples.
anda	Contamination of reagents	 A new tip must be used for each addition of different samples or reagents during the assay procedure.
t St	Contents of wells	Verify that the sealing film is firmly in place before placing
Deficient	evaporated Improper pipetting	 the assay in the incubator or at room temperature. Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
	Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.

References

- (1) O'Donnell, L.C., Druhan, L.J., Avalos, B.R. (September 2002). Molecular Characterization and Expression Analysis of Leucine-rich alpha-2-Glycoprotein, A Novel Marker of Granulocytic Differentiation. J. Leukoc. Biol. 72 (3): 478–85. PMID 12223515
- (2) Wang, X., Abraham, S., McKenzie, J.A., Jeffs, N., Swire, M., Tripathi, V.B., Luhmann, U.F., Lange, C.A., Zhai, Z., Arthur, H.M., Bainbridge, J.W., Moss, S.E., Greenwood, J. (July 2013). LRG1 Promotes Angiogenesis By Modulating Endothelial TGF-β signaling. *Nature* 499 (7458): 306–11. PMID 23868260
- (3) Vargas, I.M. (2009-06-23). A Urine Test for Appendicitis?. *HarvardScience Press Release*. Harvard College. Retrieved 2009-06-25.
- (4) Andersen, J.D., Boylan, K.L., Jemmerson, R., Geller, M.A., Misemer, B., Harrington, K.M., Weivoda, S., Witthuhn, B.A., Argenta, P., Vogel, R.I., Skubitz, A.P. Leucinerich alpha-2-Glycoprotein 1 Is Upregulated in Sera and Tumors of Ovarian Cancer Patients. *Ovarian Res.* 2010 Sep 10;3:21. doi: 10.1186/1757-2215-3-212. PMID 0831812

Version 1.0

10 March 2015